Potential Effects of Cannabidiol as a Wake-Promoting Agent

Eric Murillo-Rodríguez1,*, Andrea Sarro-Ramírez1, Daniel Sánchez1, Stephanie Mijangos-Moreno1, Alma Tejeda-Padrón1, Alwin Poot-Aké1, Khalil Guzmán2, Elda Pacheco-Pantoja3 and Oscar Arias-Carrión4

1Laboratorio de Neurociencias Moleculares e Integrativas, Escuela de Medicina, División Ciencias de la Salud, Universidad Anáhuac Mayab, Mérida, Yucatán, México; 2Departamento de Neuropatología Molecular, Instituto de Fisiología Celular Universidad Nacional Autónoma de México, México D.F. México; 3Escuela de Medicina, División Ciencias de la Salud, Universidad Anáhuac Mayab, Mérida, Yucatán. México; 4Unidad de Trastornos del Movimiento y Sueño (TMS), Hospital General “Dr. Manuel Gea González”, México D.F. México

Abstract: Over the last decades, the scientific interest in chemistry and pharmacology of cannabinoids has increased. Most attention has focused on Δ9-tetrahydrocannabinol (Δ9-THC) as it is the psychoactive constituent of Cannabis sativa (C. sativa). However, in previous years, the focus of interest in the second plant constituent with non-psychotropic properties, cannabidiol (CBD) has been enhanced. Recently, several groups have investigated the pharmacological properties of CBD with significant findings; furthermore, this compound has raised promising pharmacological properties as a wake-inducing drug. In the current review, we will provide experimental evidence regarding the potential role of CBD as a wake-inducing drug.

Keywords: Dopamine, hypothalamus, marijuana, sleep, sleepiness.

INTRODUCTION

Molecular Structure of Marijuana Derivates

Marijuana, hashish, bhang amongst others are different names given to derived-products from the plant C. sativa [1]. Among the molecules that constitute marijuana, Δ9-THC and CBD are the most significant compounds (Fig. 1) [2]. Whereas Δ9-THC is the psychoactive molecule that binds to the CB1 cannabinoid receptor and induces behavioral, neurochemical and molecular effects [3]; CBD does not promote psychotropic disturbances [4]. Moreover, recent evidence suggests that CBD is a compound with potential medical uses.

Biological Effects of Cannabidiol

Despite the fact that CBD does not bind to the CB1 cannabinoid receptor and lacks the psychotomimetic and other psychotropic effects, this cannabinoid modulates several biological functions. Current experimental data suggests that CBD is a potential candidate to be used as a therapeutic in specific medical treatments. For instance, it has been previously described that CBD acts as an anti-inflammatory and anxiolytic compound and modulates psychiatric disorders [5]. Furthermore, Martín-Santos et al., (2012) showed that when given orally CBD (600mg) no signs of anxiety, dysphoria, or physiological effects were observed in healthy male subjects [6]. Moreover, Das et al., (2013) reported that CBD can enhance consolidation of extinction learning in humans suggesting that this cannabinoid may have potential as an adjunct to extinction-based therapies for anxiety disorders [7]. Several studies provide more evidence that CBD possesses pharmacological potential, including anxiolytic, antipsychotic, antiemetic and anti-inflammatory properties [4b, 8]. In the following sections, this review will discuss the hypothesis that CBD modulates the sleep-wake cycle.

Fig. (1). Molecular structures of delta-9-tetrahydrocannabinol (Panel A) and cannabidiol (Panel B).

MODULATION OF SLEEP-WAKE CYCLE BY CANNABIDIOL

Whereas it has been well established that Δ9-THC promotes sleep [9], contradictory results on the effect of CBD on sleep were reported. For instance, Monti (1977) found a diminution in sleep after systemic administration of CBD [10], whereas Carlini and Cunha (1981) showed an improvement in sleep in insomniacs after using CBD [11].
Moreover, systemic administration of CBD (10 or 40 mg/kg) in male Wistar rats during the light period, enhanced the total percentage of sleep [12]. Further complexity has been added to the understanding of CBD pharmacology since Nicholson et al. (2004) found that 15 mg of CBD administered to young adults increased wakefulness (W) during sleeping time [13]. In addition, our laboratory provided further evidence supporting the wake-inducing properties of CBD, as i.c.v. administrations of CBD (10 µg/5 µL) in rats during the lights-off period increased W, but decreased rapid eye movement (REM) sleep. The alertness was observed after the first hour post-injection [14]. A similar effect on sleep was observed when CBD was injected into the lateral hypothalamus [15] suggesting that CBD behaves as a wake-promoting compound. Supporting this observation, it was also found that this cannabinoid increased c-Fos expression in wake-related brain areas, such as hypothalamic nuclei as well as dorsal raphe nuclei (DRN). These findings were in concordance with previous reports [16]. Even though the mechanism of sleep modulation by CBD remains unclear, our group hypothesized that the dopamine (DA) system could be involved since it has been demonstrated that microinjections of CBD (10 µg/1 or 5 µL) in rats promotes an enhancement in the extracellular levels of DA [14, 17].

Despite the wake-inducing effects caused by CBD, it remained the contradictory data reported by others. One possible explanation could lie in the differences described in the methodological procedures (route of administration, vehicle used, doses, subjects, etc). For example, in some reports, CBD was given systemically whereas others administered it centrally (either i.c.v or perfused directly into lateral hypothalamus). Moreover, some authors reported doses of 40 mg/kg whereas others used a maximal dose of CBD 20 µg/µL. Despite the methodological differences reported, further experiments will be needed to clarify the potential mechanism of action of CBD on sleep modulation.

Putative Mechanisms of Action of Cannabidiol on Waking

Despite the lack of solid evidence concerning the role of CBD on sleep modulation, we can draw the following putative mechanism of action:

**Neuroanatomical Basis**

_Hypothalamus._- Central administration of CBD enhances c-Fos expression in the hypothalamus [14]. Several reports suggest a key role of hypothalamus in the modulation of alertness [18].

_Dorsal raphe nuclei._- Central administration of CBD enhances c-Fos expression in DRN [14]. It is known that electrophysiological activity of DRN is higher in the waking state and decreases during sleep, being virtually absent in REM sleep [19].

**Neurochemical Basis**

Using a microdialysis approach, DA contents collected from AcbC have been found enhanced after central administration of CBD [14, 17]. This result was further confirmed by using other experimental techniques [20].

**Integrative Perspective**

It is known that lesions of DA neurons reduce arousal in animal models [21], as well as in Parkinson’s disease patients that present sleep dysfunction such as excessive daytime sleepiness [22]. Therefore, we postulate that alertness induced by CBD may be associated with the increase in DA release. If CBD induces alertness via activation of neurons in the hypothalamus and promotes the enhancement in DA levels, it would suggest that the enzymatic process involved in the formation of catecholamines may be under the influence of CBD. Complementary experiments testing the role of CBD on the biosynthesis of catecholamines would provide us a better understanding of the phenomena. Although this hypothesis would provide scope for speculation on the mechanism of action of CBD on sleep modulation, it might give new insights regarding the role of CBD on the sleep-wake cycle mechanisms (Fig. 2).

**The Potential Therapeutic use of Cannabidiol on Sleep Disorders**

Sleep disturbances display a range of different polysomnographic features classified as sleep disorders. According to the International Classification of Sleep Disorders (ICSD, 2001), the sleep disorders are classified into four categories [23]:

I. **Dyssomnias:** Problems initiating and maintaining sleep, and also excessive sleepiness

II. **Parasomnias:** Disorders of arousal, partial arousal, or sleep stage transition

III. Sleep disorders associated with mental, neurologic, or other medical disorders

IV. **Other sleep disorders:** Sleep disorders not included in categories I, II or III
Epidemiological data obtained from the National Sleep Foundation (NSF) Poll 2008 (USA) showed that 36% of subjects reported that they had fallen asleep while driving. Moreover, the NSF 2012 Sleep in America® poll showed that pilots are most likely to report sleep-related job performance. For example, pilots (23%) admitted that sleepiness has affected their job performance. These striking data suggest a presence of general sleep disturbances and indicate the importance of exploring new therapeutic approaches to managing sleepiness. Thus, based on experimental evidence, it could be interesting to explore the potential therapeutic properties of the use of CBD to treat and manage sleepiness. The ICSD defines somnolence as sleep episodes that are present during the alertness that require mild to moderate attention. Somnolence might occur as a secondary health condition, such as side effects of medication, illicit substance use, or obstructive sleep apnea [24]. The use of CBD for different medical purposes has been recently suggested due to it improves symptoms of several disorders (for a comprehensive review see [25]).

CONCLUSION AND PERSPECTIVES

Several pieces of evidence have shown that CBD acts as a positive compound in different treatments to manage several health conditions, such as psychiatric and neurodegenerative disorders [5a, b, 8c, 26]. Thus, it could be plausible to consider the use of CBD to explore its medical properties in somnolence. The current review highlights the pharmacological evidence on the effects of CBD on sleep modulation and provides a putative mechanism of action. For a better understanding of the molecular and neuroanatomical mechanism by which CBD regulates sleep, this subject should be further investigated.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1] Lamarine, R. J., Marijuana: modern medical chimera. J. Drug Educ. 2012, 42 (1), 1-11. doi.org/10.2190/DE.42.1.b
[2] (a) Mechoulam, R.; Shani, A.; Edery, H.; Grunfeld, Y. Chemical basis of hashish activity. Science, 1970, 169 (3945), 611-2. doi.org/10.1126/science.169.3945.611. (b) Mechoulam, R., Marihuanu chemistry. Science, 1970, 168 (3936), 1159-66. doi.org/10.1126/science.168.3936.1159. (c) Sharma, P.; Murthy, P.; Bharath, M. M. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iranian J. Psychiatry, 2012, 7 (4), 149-56. PMID: 23408483
[3] (a) Gertsch, J.; Pertwee, R. G.; Di Marzo, V. Phytocannabinoids and the cannabinoid CB1 receptor: an update. J. Pharm. Pharmacol., 2010, 62 (8), 869-76. doi.org/10.1111/j.1471-6981.2010.01030.x
[4] (a) Zuardi, A. W. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev. Bras. Psiquiatr., 2003, 25 (3), 271-80; doi.org/10.1590/S1516-44642003000300015 (b) Bergamaschi, M. M.; Queiroz, B. H.; Zuardi, A. W.; Crippa, J. A., Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr. Drug Safety, 2011, 6 (4), 237-49. doi.org/10.2174/157488611798280924
[5] (a) Campos, A. C.; Moreira, F. A.; Gomes, F. V.; Del Bel, E. A.; Guimarães, F. S. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philosophical Transactions of the Royal Society of London. Series B, Biol. Sci., 2012, 367 (1607), 3364-78. doi.org/10.1098/rstb.2011.0389 (b) Leweke, F. M.; Piemelli, D.; Pahlisch, F.; Muhl, D.; Gerth, C. W.; Hoyer, C.; Klosterkotter, J.; Hellmich, M.; Koethe, D. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry 2012, 2, e94 doi.org/10.1038/tp.2012.15 (c) Schier, A. R.; Ribeiro, N. P.; Silva, A. C.; Hallak, J. E.; Crippa, J. A.; Nardi, A. E.; Zuardi, A. W., Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Rev. Bras. Psiquiatr., 2012, 34 Suppl 1, S104-10. doi.org/10.1516/S1516-4464(12)70057-0 (d) Sagredo, O.; Pazos, M. R.; Valdeolivas, S.; Fernandez-Ruiz, J., Cannabinoids: novel medicines for the treatment of Huntington's disease. Recent Patents on CNS Drug Discov., 2012, 7 (1), 41-8. doi.org/10.2174/15748981978842278
[6] Martin-Santos, R.; Crippa, J. A.; Batalla, A.; Bhattacharyya, S.; Atakan, Z.; Borgwardt, S.; Allen, P.; Seal, M.; Langor, K.; Farre, M.; Zuardi, A. W.; McGuire, P. K. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr. Pharm. Design, 2012, 18 (32), 4966-79. doi.org/10.2174/138161212808748780
[7] Das, R. K.; Kamboj, S. K.; Ramadas, M.; Yogan, K.; Gupta, V.; Redman, E.; Curran, H. V.; Morgan, C. J. Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology, 2013, 226 (4), 781-92. doi.org/10.1007/s00213-012-2955-y
[8] (a) Izzo, A. A.; Borrelli, F.; Capasso, R.; Di Marzo, V.; Mechoulam, R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol. Sci., 2009, 30 (10), 515-27; doi.org/10.1016/j.tips.2009.07.006 (b) Scuderi, C.; Filippis, D. D.; Iuvone, T.; Blasio, A.; Steardo, A.; Esposito, G. Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother. Res. 2009, 23 (5), 597-602; doi.org/10.1002/tr.2625 (c) Fernandez-Ruiz, J.; Sagredo, O.; Pazos, M. R.; Garcia, C.; Pertwee, R.; Mechoulam, R.; Martinez-Orgado, J. Cannabidiol for neurodegenerative disorders in animal models. J. Clin. Pharmocol., 2013, 53 (2), 323-33. doi.org/10.1111/j.1600-1625.2012.03431.x
[9] (a) Pivik, R. T.; Zarcone, V.; Dement, W. C.; Holister, L. E., Delta-9-tetrahydrocannabinol and synex: effects on human sleep patterns. Clin. Pharmacol. Ther., 1972, 13 (3), 426-35; PMID: 4337346 (b) Feinberg, I.; Jones, R.; Walker, J. M.; Cavness, C.; March, J. Effects of high dosage delta-9-tetrahydrocannabinol on sleep patterns in man. Clin. Pharmacol. Ther., 1975, 17 (4), 458-66; PMID:164314 (c) Feinberg, I.; Jones, R.; Walker, J. M.; Cavness, C.; Floyd, T. Effects of marijuana extract and tetrahydrocannabinol on electroencephalographic sleep patterns. Clin. Pharmacol. Ther., 1976, 19 (6), 782-94. PMID:178475
[10] Monti, J. M. Hypnotic and psychomotor effects of cannabinoids on sleep. Psychother. Res. 1977, 55 (3), 263-5; doi.org/10.1007/BF00497858
[11] Carlini, E. A., Cunha, J. M. Hypnotic and antiepileptic effects of cannabidiol. J. Clin. Pharmacol., 1981, 21 (8), 407-15. doi.org/10.2165/00004978-19812108-00007
[12] Chagas, M. H.; Crippa, J. A.; Zuardi, A. W.; Hallak, J. E.; Machado-de-Sousa, J. P.; Hirotsu, C.; Maia, L.; Tufik, S.; Andersen, M. L. Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. J. Psychopharmacol., 2013, 27 (3), 312-6. doi.org/10.1177/0269704412475425
[13] Nicholson, A. N.; Turner, C.; Stone, B. M.; Robson, P. J. Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J. Clin. Pharmacol., 2004, 44 (3), 305-13. doi.org/10.1177/0014216503258291
[14] Murillo-Rodriguez, E.; Millan-Alcido, D.; Palomero-Rivero, M.; Mechoulam, R.; Drucker-Colin, R. Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS lett., 2006, 580 (18), 4337-45. doi.org/10.1016/j.febslet.2006.04.102
[15] Murillo-Rodriguez, E.; Millan-Alcido, D.; Palomero-Rivero, M.; Mechoulam, R.; Drucker-Colin, R. The nonpsychomotor Cannabis
Cannabinoids inhibit the synaptic uptake of adenosine and dopamine in the rat and mouse striatum. Eur. J. Pharmacol., 2011, 655 (1-3), 38-45; doi.org/10.1016/j.ejphar.2011.01.013 (b) Casarejos, M. J.; Peruchó, J.; Gomez, A.; Munoz, M. P.; Fernandez-Estevez, M.; Sagredo, O.; Fernandez Ruiz, J.; Guzman, M.; de Yebenes, J. G.; Mena, A. Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. J. Alzheimer’s Dis., 2013, 35 (3), 525-39. doi: 10.3233/JAD-130050.

(a) Jones, B. E.; Bobillier, P.; Pin, C.; Jouvet, M. The effect of lesions of catecholamine-containing neurons upon monoamine content of the brain and EEG and behavioral waking in the cat. Brain Res., 1973, 58 (1), 157-77 doi.org/10.1016/0006-8993(73)90830-5 (b) Cano, J.; Garcia-Uria, J.; Machado, A.; Reinoso-Suarez, F. Effect of cerebellar lesions on monoamine levels in various brain areas of the cat. J. Neurochem., 1980, 35 (6), 1446-8. doi.org/10.1111/j.1471-4159.1980.tb00921.x

(a) Rye, D. B.; Jankovic, J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology, 2002, 58 (3), 341-6 doi.org/10.1212/WNL.58.3.341 (b) Paus, S.; Brecht, H. M.; Koster, J.; Seeger, G.; Klockgether, T.; Wullner, U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson’s disease. Mov. Disorders : Official J. Mov. Disorder Soc., 2003, 18 (6), 659-67. doi.org/10.1002/mds.10417 (c) Feve, A. P. Current status of tyrosine hydroxylase in management of Parkinson’s disease. CNS Neurol. Disorders Drug Targets 2012, 11 (4), 450-5. doi:10.2174/187152712800792910 (d) Videnovic, A.; Golombek, D., Circadian and sleep disorders in Parkinson’s disease. Exper. Neurol., 2013, 243, 45-56; doi.org/10.1016/j.expneurol.2012.08.018 (e) Maass, A.; Reichmann, H. Sleep and non-motor symptoms in Parkinson’s disease. J. Neural Transm., 2013, 120 (4), 565-9. doi.org/10.1007/s00702-013-0966-4

Cartwright, R. Sleep-related violence: does the polysomnogram help establish the diagnosis? Sleep Med., 2000, 1 (4), 331-335. doi.org/10.1016/S1389-9457(00)00050-2

Page, J. F. Excessive daytime sleepiness. Am. Family Phys., 2009, 79 (5), 391-6.

Mechoulam, R.; Peters, M.; Murillo-Rodriguez, E.; Hanus, L. O. Cannabidiol–recent advances. Chem. Biodiversity, 2007, 4 (8), 1678-92. doi.org/10.1002/cbdv.200790147

(a) Deiana, S. Medical use of cannabis. Cannabidiol: a new light on the history of cannabis views of dopamine in schizophrenia? Drug Testing Analysis, 2013, 5 (1), 46-51; doi.org/10.1002/dta.1425 (b) Flacheckner, P. A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany. Expert Rev. Neurother., 2013, 13 (3 Suppl 1), 15-9. doi.org/10.1586/ern.13.1